var myjson = [{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':180,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':20,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Text Copy','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'210','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'240','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver','dimension12':'Gary Nachman (263)','dimension11':'LCI-NYSE: Lannett (1785)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-12T21:55:28.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ff0fb16c-d8c0-4ee7-a3f4-0d8bf2e5f8a6','page_title':'Updating Model Post Good FY1Q, Raised Guidance; NT Levo Benefit Key Driver'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':180,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Text Copy','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'210','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'240','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'270','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Text Copy','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'210','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'240','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Text Copy','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'210','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':180,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'9f68f93f080482a40fc7dcd5e96d326e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'a67e5f6446f7fe4f500af1b228a330dd','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'b3534f5045e68842d8ceeb9946ee8e98','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d41d8cd98f00b204e9800998ecf8427e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'e08341ebedc9cfebbb1fe78e4717eb0e','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Image Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':100,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':120,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':150,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':180,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':210,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Fast','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Text Copy','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'120','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'150','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'180','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'210','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'240','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'270','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'300','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'360','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'420','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'480','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':80,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'60','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'80','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'40','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'30','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Click','event_action':'Link Click','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'20','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'10','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'15','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Timing','event_action':'5','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'fb61878451d81f7c5deb11dde460e4de','dimension9':'Adjusting Model After Taking a Step Forward in 3Q','dimension12':'Gary Nachman (263)','dimension11':'VRX-NYSE: Valeant Pharmaceuticals (1422)','dimension14':'Specialty Pharmaceuticals (91)','dimension8':'2017-11-13T00:27:16.00','dimension7':'comments','dimension10':'United States','event_category':'Pageview','page_path':'/research/ffbcc394-d565-4ee9-98da-f797346f92e1','page_title':'Adjusting Model After Taking a Step Forward in 3Q'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Pageview','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'5','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'10','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'15','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'20','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'25','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Pageview','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'5','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'d7f4d70cae5e27fcf012e38e5864fb20','dimension9':'Spin-Off Ahead of Schedule','dimension12':'Richard Carlson (48)','dimension11':'DLPH-NYSE: Delphi (1670)','dimension14':'Autos/Mobility Equipment & Technology (205)','dimension8':'2017-11-13T21:51:13.00','dimension7':'flashes','dimension10':'United Kingdom','event_category':'Timing','event_action':'10','page_path':'/research/9150f587-f815-4710-b185-0f6e1b7aefc6','page_title':'Spin-Off Ahead of Schedule'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0417c9b9148aedf5d492cfde948086f8','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Image Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0aba19b0590f7ca23df4fec66a51ebf1','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'0cc175b9c0f1b6a831c399e269772661','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Image Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Text Copy','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'120','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'150','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'3b2b25c10c856e85b1dc1685d8667de2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Image Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':60,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'120','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'150','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'50181f7ddd6a89b2404c3b9ec8ccedc0','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'5f2de58b2acaa274c14961ee1837555f','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'120','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'618755e457b4ba61e4f6f4287c8a20b2','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'690ee062782400f67c39dc631ae76e32','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Image Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Fast','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'120','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'150','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'180','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'210','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Image Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'81fbc1c01369bdd803683c82a0fe6b1a','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Click','event_action':'Link Click','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'88f422f15062901b41d60eb5988c62d7','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':20,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':25,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':30,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':40,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':50,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Gentle','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Flash','event_label':15,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'40','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'60','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'80','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'120','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'150','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'100','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':10,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'20','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'30','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'10','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'15','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'25','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'50','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Percentage','event_action':'75','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Scroll Speed','event_action':'Stationary','event_label':5,'page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'902dff8ba0654ad59ec30e175b3f848b','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Timing','event_action':'5','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'},{'dimension3':'9cdaf6e5104160d4b3333bc55ba12385','dimension9':'Q3 Earnings Below Our Estimate','dimension12':'Jonathan Lamers (150)','dimension11':'HLF-TSX: High Liner Foods (1663)','dimension14':'Special Situations (92)','dimension8':'2017-11-14T05:46:58.00','dimension7':'comments','dimension10':'Canada','event_category':'Pageview','page_path':'/research/64e5a5fb-0a4d-4a51-94f1-556904ff5b27','page_title':'Q3 Earnings Below Our Estimate'}]